VEIL.AI is a trusted partner for the world’s leading pharmaceutical companies, helping them navigate the complexities of sensitive health data. Our technology empowers you to maximize data utility without sacrificing privacy or regulatory compliance. Proven across clinical trials, health economics studies, and cross-border research, our solutions ensure that your data remains secure, compliant, and ready for any “Data for AI” application.
Maintain the quality and utility of your data with next-generation anonymization that preserves essential details.
Use privacy preserving technology to meet the rigorous standards of GDPR, the EU AI Act, and US NIST guidelines.
Securely train and validate artificial intelligence systems with anonymous high quality data, compliant with GDPR and the EU AI Act.
Seamlessly share and utilize data across borders with full compliance under the European Health Data Space framework.
This is a significant achievement. In our study, we could draw the same conclusions from anonymized data as from traditional pseudonymized, individual-level research data.
Strategic Project Lead, BAYER
VEIL.AI’s anonymization technology enables the creation of robust virtual control arms for clinical trials. Our technology ensures that anonymized real-world data (RWD) can be used effectively, increasing the statistical power of your trials while adhering to the highest privacy standards.
Our next-generation anonymization technology helps you unlock value from historical randomized controlled trial (RCT) data restricted by initial consent agreements. By anonymizing legacy RCT data, you can perform secondary analysis, validate new treatments, and repurpose data for future trials without compromising patient privacy or regulatory compliance.
Next-generation anonymization enables the use of RWD for AI/ML model training without compromising data privacy. Our technology ensures that the data fed into your models remains anonymized, while still being of high quality and relevance. This allows you to build, train, and refine AI models for healthcare applications with confidence in data security and compliance.
Real-world evidence (RWE) is key in gaining market access and demonstrating health outcomes for new therapies. VEIL.AI’s next-generation anonymization helps you securely anonymize RWD, enabling you to create robust RWE without breaching privacy regulations. Use anonymized RWE to substantiate the value of your innovations in health economics, market access, and regulatory submissions.
VEIL.AI empowers global clinical research by enabling the secure and compliant sharing of sensitive health data across borders. Our technology meets the highest privacy standards, including GDPR and EHDS, allowing for seamless international collaboration that accelerates research and innovation.
Maintaining patient privacy while utilizing health data is a big concern. VEIL.AI provides comprehensive privacy risk assessments and anonymity verification tools and services, ensuring that the anonymized data meet all legal and ethical standards. Findata, the Finnish Social and Health Data Permit Authority, has approved our protocol to verify anonymity before releasing the anonymous data for secondary use.
Global life science company Bayer carried out a four-year multi-million-euro development project called Future Clinical Trials (FCT), which utilized AI-enhanced next-generation anonymization technology from VEIL.AI. Our unique technology enabled the secure and efficient use of high-quality, anonymized data approved by Findata. For the first time, Findata approved the data as GDPR-compliant, allowing its transfer across borders for further enrichment and innovative research.
This case demonstrates:
VEIL.AI designed a study together with our partners Bayer and MedEngine to compare the use of anonymized and pseudonymized Real-World Data (RWD) in creating external control arms (ECAs) for single-arm randomized controlled trials (RCTs) .
The study, published in BMC Medical Research Methodology, showed that one could draw the same conclusions from anonymized data as from traditional pseudonymized, individual-level research data.
Bayer Future Clinical Trials project faced the challenge of leveraging extensive legacy data for new research purposes. VEIL.AI provided Bayer high quality, individual-level anonymized data, enabling secondary use of data for research without breaching original consent agreements. This not only extended the utility of existing data but also empowered Bayer to conduct new studies with rich, compliant data, ensuring both privacy and high data quality.
This case demonstrates:
Leverage our secure and scalable cloud platform, where we manage the deployment and maintenance, allowing you to focus on your core operations.
Our anonymization stack can be deployed to your architecture and you host it. It can be deployed to almost any platform. Both cloud and on-premises solutions are possible. SLA is agreed according to your needs.
Benefit from our expert professional services, where our team of data scientists and privacy engineers will collaborate with you to overcome your data and privacy challenges, ensuring you achieve your objectives with confidence.
Get in touch with us to discover how VEIL.AI can help you securely anonymize your health data, enhance your research capabilities, and accelerate your time to market.
*By submitting this form you agree to our Privacy policy. We are committed to your privacy. Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about VEIL.AI and our services. You may unsubscribe from these communications at any time.
Dive deeper into VEIL.AI’s technology through our comprehensive whitepapers, case studies, and research articles. Learn how our technology is being applied in real-world scenarios and see the results for yourself.
VEIL.AI has launched a refreshed brand identity, updating its visual elements and refining its messaging to reflect its commitment
Health data is an increasingly important resource for innovation and research, yet cross-Atlantic data collaborations are confounded by privacy
VEIL.AI was one of 15 startups selected from among 170 applicants for the Basel-based accelerator program DayOne Health 4.0,
Join our newsletter to stay up to date on features and releases.
* By submitting you agree with VEIL.AI Privacy policy
© 2024 VEIL.AI. All rights reserved